surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 New Blockbuster Medication Mounjaro Gets FDA Approval Tirzepatide for the Maintenance of
Description
Limiting high-fat and fried foods may reduce gastrointestinal side effects
[DOI] [PubMed] [Google Scholar] 29.Aroda VR, Bain SC, Cariou B, et al
It was the first study to report an association between GLP-1 and NAION The study divided patients with type 2 diabetes or who were overweight/obese into groups based on whether they were prescribed a GLP-1 medication or non-GLP-1 RA medications
off-label (for people without the FDA-approved indication)
It acts on the appetite center in your hypothalamus, slows gastric emptying so food stays in your stomach longer, stimulates insulin release when blood sugar is elevated, and suppresses glucagon
A provider must determine whether Tirzepatide is clinically appropriate based on medical history, goals, and safety factors
